<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="71041">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180958</url>
  </required_header>
  <id_info>
    <org_study_id>NV-ONY-002</org_study_id>
    <nct_id>NCT02180958</nct_id>
  </id_info>
  <brief_title>ONYX Evaluation in the Endovascular Treatment of Cerebral Arteriovenous Malformations (cAVM)</brief_title>
  <acronym>cAVM</acronym>
  <official_title>Assessment of ONYX in Endovascular Cerebral AVM. Prospective, Multi-centre and Observational French Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Neurovascular Clinical Affairs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Neurovascular Clinical Affairs</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the safety at 1 month after any embolization
      session and the efficacy at:

        -  12 months post last embolization in case of treatment with embolization only

        -  12 months after additional treatment with neurosurgery

        -  36 months after additional treatment with radiosurgery
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>To assess safety</measure>
    <time_frame>At 1 month after embolization</time_frame>
    <description>Evaluation of the number of events, related to the device or the procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the performance (healing)</measure>
    <time_frame>At 12 or 36 months after embolization</time_frame>
    <description>Evaluation of healing rate at:
12 months after last embolization in case of complete treatment or stopping treatment;
12 months after additional intervention in case of additional treatment required by neuro-surgery;
36 months after additional intervention in case of additional treatment required by radio-surgery.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cerebral Arteriovenous Malformations</condition>
  <arm_group>
    <arm_group_label>Cerebral Arteriovenous Malformations</arm_group_label>
    <description>Adult patients requiring endovascular treatment of Cerebral Arteriovenous Malformations.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All the patients from participating centres for whom a cerebral AVM (not already treated)
        has to be treated (whatever treatment method anticipated) and who do not object to the
        collection and transmission of data concerning them, will be included in the so-called
        &quot;screened&quot; population.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient presents a cerebral AVM (not already treated) that can be treated by
             embolization with Onyx whether or not associated with a cyanoacrylate based adhesive,

          -  The patient is at least 6 years old.

        Exclusion Criteria:

          -  During the treatment period for his/her cerebral AVM, the patient participates in a
             study assessing another medical device, another procedure or a drug.

          -  The patient and/or his/her legal representative (if applicable) refuses to give
             his/her consent to the collection and processing of data required by the centralized
             follow-up. For patients who refused collection of their personal data, only, the
             reason for non inclusion and date of implantation will be documented.

          -  Any condition that could prevent follow-up of the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric Ricolfi, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Dijon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Courthéoux, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe Cognard, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurent Spelle, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Beaujon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Vicaut, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Lariboisière-Fernand Vidal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maura Power</last_name>
    <phone>+353 1 438 1630</phone>
    <email>maura.power@covidien.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covidien</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 27, 2016</lastchanged_date>
  <firstreceived_date>April 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cerebral arteriovenous malformations</keyword>
  <keyword>cAVM</keyword>
  <keyword>ONYX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Arteriovenous Malformations</mesh_term>
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Intracranial Arteriovenous Malformations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
